Graphite Bio leads this week's IPO squad, look­ing to turn the tide on sick­le cell dis­ease with gene edit­ing

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

Biotech’s IPO march con­tin­ued ear­li­er this week with …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER